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ABSTRACT 
Objective: To study the stability profile of floating microspheres of repaglinide as per ICH guidelines under normal (25±2°C/60±5% RH) and 
accelerated condition (40±2°C/75±5% RH and 5-8°C/65±5% RH) for a period of six mo. 
Methods: Floating microspheres were prepared using ethylcellulose (EC) and hydroxypropyl methylcellulose (HPMC) and subjected to stability 
studies. Physical appearance, scanning electron microscopy (SEM), % buoyancy, % residual drug content and drug release of stored formulation 
were evaluated after every two mo.  
Results: Change in color, size, and residual drug content showed no significant variations in formulations stored at a different set of conditions. SEM 
images showed no morphological transformation during the study. Less than 5% change was observed in buoyancy and drug release.  
Conclusion: The data depict that the formulation is sufficiently rugged for marketing worldwide under various climatic conditions including 
normal, oven and freezing temperature. 
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Drug development process plays a key role in achieving scientific 
success and commercial launching of the drug product. During the 
developmental stage, pharmaceutical analysis and stability studies 
are the most important steps required to determine and assure the 
identity, potency and purity in terms of ingredients, as well as 
formulated products [1].  
Definition of stability for a pharmaceutical product is the capability 
of specific formulation in a prescribed container/closure system to 
maintain its physicochemical, microbiological, toxicological, 
protective and informational integrity [2]. Thus, the effect of 
environmental factors on the quality of the drug substance or a 
formulation which is utilized for prediction of its shelf life is studied 
thoroughly. For regulatory approval of formulation predetermined 
storage conditions and proper instructions regarding labeling of a 
product is prime important during stability studies [3].  
Drug formulation’s stability testing is a complex process involving a 
variety of factors during which it may undergo a change in 
appearance, consistency, content uniformity, particle size and shape, 
moisture contents, pH, package integrity thereby affecting its 
stability. Various chemical reactions may occur in the 
pharmaceutical product such as reduction, oxidation, racemization 
and may leads to the formation of the degradation product, loss of 
excipient and active pharmaceutical ingredient (API) potency, loss of 
activity etc [4].  
Various regulatory authorities in several countries have made 
provisions for submission of data generated during stability 
studies by the manufacturers to assure the formulation of stable 
product from stable molecule to be available for patients use. 
ICH and WHO issue guidelines for smooth and planned 
conduction of stability studies and must be followed strictly for 
quality results [5, 6].  
Repaglinide is an oral hypoglycemic agent and the first member of 
meglitinide class, used to treat type-2 diabetes mellitus. Floating 
microspheres have been known for increasing therapeutic efficacy 
and enhance physical as well as the chemical stability of many drugs 
[7]. In vitro and in vivo evaluation of the formulation have been 
extensively studied and prolific results thus obtained have been 
reported previously [8].  
The objective of the present investigation is to assess the stability 
profile of optimized formulation of EC and HPMC at the normal and 
accelerated condition. As reported earlier in vitro characterization 
results shows prolonged drug release from spherical, highly 
entrapped and good buoyant floating microspheres. Excellent in vivo 
floating behavior in rat stomach for appreciable time with good 
results during histopathological studies have been reported [8]. 
Now, during stability studies, extensive work on physical 
appearance, SEM, % buoyancy, % residual drug content and drug 
release studies of the formulation at normal and accelerated 
condition for a period of six mo have been conducted. 
Repaglinide was received as gift sample from Torrent 
Pharmaceuticals, Ahmadabad, India. Ethylcellulose, Hydroxypropyl 
methylcellulose were purchased from Himedia Chemicals, India. 
Analytical grade ethanol, dichloromethane, polivinyl alcohol (PVA) 
was procured from SD fine chemicals Mumbai, India.  
Microspheres were prepared by solvent diffusion-evaporation 
technique [9]. Repaglinide (10 mg), EC: HPMC (5cps) 1:2 ratio and 
0.1% of polyethylene glycol (as surfactant) were mixed in 1:1 ratio 
of ethanol and dichloromethane. The slurry was slowly introduced 
into 80 ml of 0.46% w/v of PVA as an emulsifier and stirred at 900 
rpm for about 1 h. The floating microspheres were thoroughly 
washed 3-4 times with distilled water, dried for 1 h at room 
temperature and stored in desiccators over fused calcium chloride 
[8].  
The prepared formulation was studied for stability profile at normal 
and accelerated conditions as per ICH guidelines. The formulation 
was placed separately in amber colored borosilicate screw capped 
glass container and stored at normal room temperature (25±2 
°C/60±5% RH), freezing temperature (5-8 °C/65±5% RH) and for 
accelerated testing at oven temperature (40±2 °C/75±5% RH) 
respectively for a period of 6 mo. After every two mo the stored 
formulations were evaluated for various parameters. 
Change in color was visualized and size of the formulation was 
determined by optical microscopy (Dolphin ASI-22 5354) using an 
ocular micrometer. Morphological transformation, if any during the 
study was checked using scanning electron microscope (SEM) (Jeol 
JSM-1600, Tokyo, Japan). Floating ability was studied by placing the 
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microspheres in SGF (pH 1.2) and stirred at 100 rpm for 12 h. % 
buoyancy was calculated using formula as reported [8]. % residual 
drug content was determined by crushing the microspheres and 
dissolved in ethanol followed by filtration and analyzed at 247 nm 
using UV spectrophotometer (Shimadzu 1700). 
The release rate of the drug was examined in 0.1 N HCl using 
dissolution test apparatus (Veego, VDA-6DR, USP Std) of paddle 
type. 1 ml sample was withdrawn after 12 h filtered and analyzed 
spectrophotometrically at 247 nm.  
The stability of the pharmaceutical product is essential in a number 
of ways such as: safety of the patient, legal requirement concerned 
with the quality and purity of drug and to prevent the economic 
repercussion of marketing of the undesirable product. Several 
researchers have studied the stability profile of floating 
microspheres as per ICH guidelines [10, 11, 12]. In the present study 
stability of optimized formulation was carried out at three different 
temperatures (5-8 °C, 25±2 °C and 40±2 °C) and evaluated 
continuously after every two mo.  
Physical appearance showed no significant variation and change in 
color (table 1). Similarly, no significant change in the size of 
microspheres from initial day was reported up to 3 mo while smaller 
non-significant change was observed at end of 6 mo for the samples 
stored at refrigeration and oven temperature respectively (data not 
shown). The Little increment in particles size might be due to 
aggregation of microspheres stored in refrigerated conditions was 
observed. Formulation stored at high temperature shows no 
aggregation of microspheres as the probability of melting of the 
polymer is negligible owing to their high melting point. The particle 
size of the microspheres was found to decrease slightly at 40±2 °C 
may be due to the evaporation of residual amount of organic solvent 
at a higher temperature from the microspheres [11]. During surface 
morphology, SEM images indicate the retention of the spherical 
shape of microspheres, there was no sign of morphological 
transformation with the development of cracks or rupturing of the 
surface of stored formulations (fig. 1).  
The floating capacity was assured as the % buoyancy was not 
changed much (<5%) for the stored formulation. The % buoyancy of 
initial sample at the start of the study was 84.36±0.9 % which 
changes to 82.85±0.3, 84.02±0.4 and 82.91±0.5 % for increasing 
order of temperature selected during the study (n=3). Thus, sample 
stored at room temperature shows maximum buoyancy. The 
histogram was plotted between % buoyancy and time for 
formulations stored at different temperatures [12] and the results 
were almost similar to initial day of storage (fig. 2). To determine % 
residual drug content [13], the initial drug content of all the 
formulations was taken to be 100%. Graph between % drug content 
and time was plotted which shows no significant effect from the 
initial day (fig. 3). All datas are represented as mean±SD (n=3). A 
non-significant loss of drug was found in the sample stored at 40±2 
°C as compared to 5-8 °C and 25±2 °C which may be due to slight 
loss of integrity of the system [14]. 
Drug release was studied, and the histogram was plotted between % 
drug release and time for different formulations, which showed no 
significant change. At the end of study after 12 h release of stored 
formulation was taken and compared by plotting a graph between 
cumulative % drug release and time (fig. 4). There was no change in 
release rate at freezing and room temperature. The release is 
slightly increased (84.5±2.1 to 86.10±2.1) for formulation kept at 
oven temperature as compared to initial day release which might be 
due to the formation of more pores in the microspheres due to 
evaporation of residual amount of solvent. The results of the 
stability studies indicated that the repaglinide loaded floating 
microspheres was stable at all conditions but most stable at room 
temperature. 
The optimized formulation of repaglinide using EC and HPMC (5 
cps) having good in vitro and in vivo characteristics was formulated 
and evaluated for stability profile at three different temperature 
conditions (freezing, room and oven). The storage conditions 
employed do not have a drastic effect on microspheres integrity. 
Stability of product is thus, justified by observing the results of 
physical and chemical stableness of dosage form. Thus, it may be 
concluded that EC and HPMC microspheres of repaglinide are a 
suitable delivery system for prolonged activity having significant 
stability without losing its therapeutic activity when stored at 
different temperatures. 
 
Table 1: Physical appearance of formulation during stability study after six mo 
 Condition Color change Size Inference 
1. Normal  No change  No change Complies with stability condition 
2. Accelerated No change  No change Complies with stability condition 
 
 
Fig. 1: SEM images of microspheres: (a) Freezing temperature (b) Room temperature (c) Oven temperature 
 
 
Fig. 2: Comparison of % buoyancy and % drug release at different conditions. All datas are represented as mean±SD (n=3) 
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Fig. 3: % residual drug content of formulations at different 
temperatures. All datas are represented as mean±SD (n=3) 
 
 
Fig. 4: % cumulative drug release after six mo storage at 
different temperatures for 12 h All values are represented as 
mean±SD (n=3) 
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